Treatment Outcomes After Higher-dose Fractionated Stereotactic Radiotherapy (FSRT) Alone for 1-4 Brain Metastases

Leonie Johannwerner, Elisa M. Werner, Stefan Janssen, Nathan Y. Yu, Dirk Rades

Abstract

BACKGROUND/AIM: Fractionated stereotactic radiotherapy (FSRT) is increasingly used for brain metastases. We investigated higher-dose FSRT with biologically effective doses (BED) of 49.6-66.7 Gy12 Patients and Methods: Eleven characteristics were evaluated for local control (LC), overall survival (OS), and freedom from radiation necrosis (RN) in 69 patients with 1-4 brain metastases. Fifty-seven patients (83%) had extracranial metastases, 23 (33%) Karnofsky performance scores (KPS) ≤70, and 21 (30%) brain metastases ≥21 mm. RESULTS: At 1 and 2 years, LC-rates were 81% and 63%, OS-rates 66% and 43%, and freedom from RN-rates 98% and 87%, respectively. Median time to local progression was 35 months, median survival 19 months. KPS ≥90 was associated with better OS (p=0.048). BED of 49.6-57 Gy12 (vs. 63-66.7 Gy12) was associated with higher rates of freedom from RN (p=0.046), not with LC (p=0.78) or OS (p=0.55). CONCLUSION: Higher-dose FSRT appears feasible and effective in patients with 1-4 brain metastases. BED 63-66.7 Gy12 may not improve LC and OS but may increase RN risk.

OriginalspracheEnglisch
ZeitschriftAnticancer Research
Jahrgang43
Ausgabenummer6
Seiten (von - bis)2757-2762
Seitenumfang6
ISSN0250-7005
DOIs
PublikationsstatusVeröffentlicht - 01.06.2023

Strategische Forschungsbereiche und Zentren

  • Profilbereich: Lübeck Integrated Oncology Network (LION)
  • Zentren: Universitäres Cancer Center Schleswig-Holstein (UCCSH)

DFG-Fachsystematik

  • 205-30 Radiologie, Nuklearmedizin, Strahlentherapie, Strahlenbiologie
  • 205-14 Hämatologie, Onkologie

Fingerprint

Untersuchen Sie die Forschungsthemen von „Treatment Outcomes After Higher-dose Fractionated Stereotactic Radiotherapy (FSRT) Alone for 1-4 Brain Metastases“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren